The UK and US have secured a major bilateral deal that will keep no levies on UK medicine exports being sold in the American market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to boost expenditure on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that duties on these crucial goods will be held at zero for a timeframe of 36 months.
This deal follows previous warnings to significantly raise duties on branded pharmaceutical imports, with figures floated up to double the cost.
"This deal between the United Kingdom bolsters the worldwide climate for new treatments and brings long-overdue fairness to American-British pharmaceutical trade," an announcement declared.
Commercial Significance
Medicines constitute one of the UK's biggest exports to the US, which is by far the primary buyer for leading companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period prior to the third quarter, the UK shipped pharmaceutical products worth £11.1bn to the US. This value made up nearly one-fifth of British export trade in that period.
"This guarantee protects employment, boosts funding and facilitates the UK to become a international leader for life sciences," the Business and Trade Secretary stated.
Detailed UK Commitments
The agreement entails several specific commitments from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a target to double total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Payback Limit: The sum pharmaceutical firms must refund to the NHS to prevent overspending will be limited at 15%. In the past, repayments were more than 20%.
Recent Tensions
This agreement comes amid a ongoing tension between the drug companies and the UK government over medicine costs and regulatory access.
These tensions were heightened by assertions that American consumers were paying significantly more for the equivalent treatments than people in the Britain and the EU.
In recent months, several large drug company projects in the UK have been halted or scrapped, while substantial investments have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had shrunk as a proportion of its resources over the previous ten-year period.
